Funded Tech Companies
Rapafusyn Pharmaceuticals
Researching who provided funding to Rapafusyn Pharmaceuticals? Proxima Ventures, Lapam Capital and 3E Bioventures invested in this biopharmaceutical company.
Company Overview
Company Name
Rapafusyn Pharmaceuticals
Company Status
Private & Independent
Industry
Funding Rounds
Total Funding
Contact Information
Mailing Address
855 N. Wolfe Street
Baltimore, MD 21205
USA
Baltimore, MD 21205
USA
Phone
Website
Email Address
Company Background Information
Overview
At Rapafusyn, we are developing non-degrading molecular glues to tackle difficult drug targets to improve patient outcomes. Rapafusyn has designed and generated large DNA encoded libraries (DELs) and arrayed libraries of non-degrading molecular glues (RapaGlues�) that are designed on a FKBP-binding macrocyclic peptide platform. These libraries have been successful in generating novel chemical starting points for hard-to-drug targets, often with cell permeability right from screening. Moreover, as our molecules are molecular glues, the target-binding peptidic portion is more tunable than traditional macrocyclic peptides.
Profile
Social Media
Company News
Facebook
YouTube
Last Transaction
6/24/2024
Financing History
Date
Type
Amount
Management Team
Title
Name
Email & Social
Chief Executive Officer
Sean Hu
Vice President
Rick Ewing
Vice President
Matthew Olson
VP - Bus. Development
Matthew Gross
Company Investors
- Proxima Ventures
- Lapam Capital
- 3E Bioventures
Browse more funded tech companies:
Share this article
About Our Venture Capital Database
Our data comes from VentureDeal.com, a leading supplier of venture capital funding data.
Additional Resources for Entrepreneurs